Share Price and Basic Stock Data
Last Updated: November 8, 2025, 3:59 am
| PEG Ratio | 259.07 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
SMS Pharmaceuticals Ltd operates in the pharmaceuticals sector and reported a market capitalization of ₹2,807 Cr, with its stock priced at ₹300. The company has shown a fluctuating revenue trend over recent quarters. Quarterly sales stood at ₹64 Cr in Jun 2022, peaking at ₹246 Cr in Mar 2024 before slightly declining to ₹164 Cr in Jun 2024. For the financial year ending Mar 2025, the total sales were reported at ₹783 Cr, reflecting a growth from ₹522 Cr in Mar 2023. The trailing twelve months (TTM) revenue reached ₹814 Cr, indicating a solid upward trajectory. The company’s operating profit margin (OPM) was reported at 20%, which is competitive compared to industry averages, suggesting effective cost management. Notably, the revenue from operations per share increased to ₹88.29 in Mar 2025 from ₹61.67 in Mar 2023, showcasing an improving operational efficiency. Overall, SMS Pharmaceuticals has demonstrated resilience in its revenue performance despite challenges, providing a promising outlook in the pharmaceutical industry.
Profitability and Efficiency Metrics
SMS Pharmaceuticals reported a net profit of ₹70 Cr for the financial year ending Mar 2025, up from a mere ₹4 Cr in Mar 2023. This significant increase highlights a turnaround in profitability, with the earnings per share (EPS) rising to ₹8.16. The company’s return on equity (ROE) stood at 11%, while the return on capital employed (ROCE) was recorded at 12.2%, indicating efficient utilization of capital. The interest coverage ratio (ICR) was strong at 7.83x, signaling that the company comfortably manages its interest obligations. However, the cash conversion cycle (CCC) stood at 238 days, which is relatively high and could affect liquidity. Furthermore, the operating profit margin (OPM) remained stable at 20%, reflecting consistent operational efficiency. The company’s ability to generate profit from its sales is commendable, yet the high CCC poses a potential risk to cash flow management. Overall, SMS Pharmaceuticals displays solid profitability metrics, albeit with room for improvement in operational efficiency.
Balance Sheet Strength and Financial Ratios
The financial stability of SMS Pharmaceuticals is underscored by its balance sheet, with total reserves reported at ₹664 Cr against borrowings of ₹311 Cr, indicating a healthy reserve-to-debt ratio. The debt-to-equity ratio stood at 0.48, suggesting manageable leverage levels compared to industry standards. The company’s current ratio was recorded at 1.71, which is above the typical benchmark of 1, reflecting a strong liquidity position. However, the quick ratio of 0.83 indicates potential liquidity concerns, as it falls below the ideal threshold of 1. The book value per share increased to ₹72.15 in Mar 2025 from ₹54.40 in Mar 2023, suggesting an enhancement in shareholder value. The total liabilities of the company rose to ₹1,186 Cr, which includes other liabilities that have shown a slight decline. SMS Pharmaceuticals appears to maintain a robust financial position; however, the balance between growth and debt management remains critical for sustained performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of SMS Pharmaceuticals reflects a strong promoter backing, with promoters holding 68.07% of the equity as of Sep 2025. This level of control is indicative of confidence from the founding shareholders in the company’s future. Foreign institutional investors (FIIs) hold a minimal stake of just 0.17%, while domestic institutional investors (DIIs) have increased their stake to 2.88%. The public shareholding has decreased to 28.88%, which could indicate a consolidation of ownership among major stakeholders. The number of shareholders stood at 33,009, showing a healthy interest from retail investors. The gradual increase in DII holdings from 0% to 2.88% over the last year may signal increasing institutional confidence in the company. However, the low foreign institutional interest may raise questions about broader market perception. Overall, the shareholding structure suggests robust internal confidence but highlights the need to boost external investor engagement.
Outlook, Risks, and Final Insight
Looking ahead, SMS Pharmaceuticals is well-positioned for growth, given its improving profitability and strong balance sheet. The revenue growth trajectory, along with a solid operational performance, supports a positive outlook. However, risks such as a high cash conversion cycle and low foreign institutional investment could impact liquidity and market sentiment. The pharmaceutical industry is known for its volatility, and potential regulatory changes could pose additional challenges. Nevertheless, if SMS Pharmaceuticals manages to enhance its operational efficiency and address liquidity concerns, it could capitalize on its market position effectively. The company’s ability to sustain profitability while expanding its market presence will be crucial. Overall, SMS Pharmaceuticals presents a mixed yet promising investment opportunity, contingent on its strategic management of operational risks and investor relations.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of SMS Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.86 | 198.43 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 64 | 159 | 149 | 149 | 135 | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 |
| Expenses | 65 | 146 | 131 | 126 | 109 | 139 | 133 | 212 | 131 | 165 | 140 | 207 | 157 |
| Operating Profit | -0 | 14 | 18 | 23 | 27 | 28 | 29 | 33 | 33 | 32 | 33 | 41 | 39 |
| OPM % | -1% | 9% | 12% | 16% | 20% | 17% | 18% | 14% | 20% | 16% | 19% | 17% | 20% |
| Other Income | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 |
| Interest | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 |
| Profit before tax | -12 | 1 | 6 | 11 | 13 | 15 | 16 | 22 | 22 | 20 | 23 | 29 | 24 |
| Tax % | -21% | 12% | 22% | 24% | 29% | 21% | 26% | 26% | 25% | 28% | 24% | 29% | 24% |
| Net Profit | -10 | 1 | 5 | 8 | 9 | 12 | 12 | 16 | 16 | 14 | 17 | 21 | 18 |
| EPS in Rs | -1.16 | 0.09 | 0.59 | 0.95 | 1.10 | 1.42 | 1.44 | 1.88 | 1.93 | 1.68 | 2.03 | 2.33 | 2.05 |
Last Updated: August 20, 2025, 3:25 am
Below is a detailed analysis of the quarterly data for SMS Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 196.00 Cr.. The value appears to be declining and may need further review. It has decreased from 248.00 Cr. (Mar 2025) to 196.00 Cr., marking a decrease of 52.00 Cr..
- For Expenses, as of Jun 2025, the value is 157.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 207.00 Cr. (Mar 2025) to 157.00 Cr., marking a decrease of 50.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 39.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2025) to 39.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 17.00% (Mar 2025) to 20.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Mar 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 29.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Mar 2025) to 24.00%, marking a decrease of 5.00%.
- For Net Profit, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 3.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.05. The value appears to be declining and may need further review. It has decreased from 2.33 (Mar 2025) to 2.05, marking a decrease of 0.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:25 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 518 | 587 | 611 | 438 | 463 | 465 | 412 | 563 | 520 | 522 | 709 | 783 | 814 |
| Expenses | 461 | 500 | 522 | 363 | 369 | 375 | 332 | 442 | 405 | 467 | 592 | 643 | 669 |
| Operating Profit | 57 | 86 | 89 | 75 | 93 | 90 | 80 | 121 | 115 | 55 | 117 | 140 | 145 |
| OPM % | 11% | 15% | 15% | 17% | 20% | 19% | 19% | 22% | 22% | 10% | 16% | 18% | 18% |
| Other Income | 2 | 16 | 4 | 1 | 2 | 3 | 5 | 3 | 5 | 5 | 4 | 6 | 5 |
| Interest | 14 | 18 | 17 | 16 | 15 | 12 | 12 | 11 | 19 | 22 | 24 | 19 | 20 |
| Depreciation | 13 | 17 | 19 | 19 | 20 | 19 | 22 | 22 | 32 | 32 | 32 | 34 | 36 |
| Profit before tax | 32 | 67 | 56 | 42 | 60 | 62 | 51 | 91 | 69 | 6 | 66 | 93 | 95 |
| Tax % | 36% | 48% | 26% | 14% | 33% | 34% | 36% | 33% | 1% | 26% | 25% | 27% | |
| Net Profit | 20 | 35 | 42 | 36 | 40 | 41 | 33 | 61 | 68 | 4 | 49 | 68 | 70 |
| EPS in Rs | 2.40 | 4.15 | 4.92 | 4.20 | 4.78 | 4.89 | 3.86 | 7.20 | 8.03 | 0.48 | 5.83 | 7.71 | 8.09 |
| Dividend Payout % | 8% | 5% | 4% | 5% | 5% | 5% | 6% | 4% | 4% | 62% | 7% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 75.00% | 20.00% | -14.29% | 11.11% | 2.50% | -19.51% | 84.85% | 11.48% | -94.12% | 1125.00% | 38.78% |
| Change in YoY Net Profit Growth (%) | 0.00% | -55.00% | -34.29% | 25.40% | -8.61% | -22.01% | 104.36% | -73.37% | -105.59% | 1219.12% | -1086.22% |
SMS Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 16% |
| 3 Years: | 0% |
| TTM: | 24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 22% |
| 3 Years: | 39% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 7% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 1:31 pm
Balance Sheet
Last Updated: June 16, 2025, 11:20 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 |
| Reserves | 213 | 246 | 286 | 254 | 293 | 331 | 359 | 420 | 485 | 487 | 562 | 664 |
| Borrowings | 167 | 167 | 204 | 149 | 146 | 144 | 157 | 255 | 263 | 254 | 281 | 311 |
| Other Liabilities | 120 | 119 | 158 | 89 | 72 | 93 | 103 | 147 | 126 | 165 | 217 | 202 |
| Total Liabilities | 509 | 540 | 656 | 501 | 519 | 577 | 627 | 830 | 883 | 914 | 1,068 | 1,186 |
| Fixed Assets | 247 | 277 | 370 | 290 | 279 | 281 | 280 | 457 | 438 | 412 | 437 | 533 |
| CWIP | 39 | 29 | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 |
| Investments | 6 | 13 | 21 | 37 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 |
| Other Assets | 217 | 221 | 252 | 166 | 187 | 232 | 259 | 321 | 389 | 424 | 556 | 573 |
| Total Assets | 509 | 540 | 656 | 501 | 519 | 577 | 627 | 830 | 883 | 914 | 1,068 | 1,186 |
Below is a detailed analysis of the balance sheet data for SMS Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 9.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Mar 2025, the value is 664.00 Cr.. The value appears strong and on an upward trend. It has increased from 562.00 Cr. (Mar 2024) to 664.00 Cr., marking an increase of 102.00 Cr..
- For Borrowings, as of Mar 2025, the value is 311.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 281.00 Cr. (Mar 2024) to 311.00 Cr., marking an increase of 30.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 202.00 Cr.. The value appears to be improving (decreasing). It has decreased from 217.00 Cr. (Mar 2024) to 202.00 Cr., marking a decrease of 15.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,186.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,068.00 Cr. (Mar 2024) to 1,186.00 Cr., marking an increase of 118.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 533.00 Cr.. The value appears strong and on an upward trend. It has increased from 437.00 Cr. (Mar 2024) to 533.00 Cr., marking an increase of 96.00 Cr..
- For CWIP, as of Mar 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Mar 2024) to 35.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Mar 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 45.00 Cr..
- For Other Assets, as of Mar 2025, the value is 573.00 Cr.. The value appears strong and on an upward trend. It has increased from 556.00 Cr. (Mar 2024) to 573.00 Cr., marking an increase of 17.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,186.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,068.00 Cr. (Mar 2024) to 1,186.00 Cr., marking an increase of 118.00 Cr..
Notably, the Reserves (664.00 Cr.) exceed the Borrowings (311.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -110.00 | -81.00 | -115.00 | -74.00 | -53.00 | -54.00 | -77.00 | -134.00 | -148.00 | -199.00 | -164.00 | -171.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 39 | 37 | 36 | 18 | 19 | 20 | 43 | 68 | 34 | 104 | 122 | 95 |
| Inventory Days | 90 | 81 | 106 | 114 | 135 | 170 | 191 | 148 | 333 | 243 | 201 | 238 |
| Days Payable | 59 | 58 | 79 | 82 | 49 | 59 | 66 | 70 | 97 | 117 | 130 | 95 |
| Cash Conversion Cycle | 70 | 61 | 63 | 50 | 105 | 131 | 169 | 146 | 270 | 230 | 192 | 238 |
| Working Capital Days | 9 | 19 | 19 | -2 | 27 | 39 | 57 | 48 | 94 | 104 | 85 | 88 |
| ROCE % | 12% | 21% | 16% | 13% | 18% | 16% | 13% | 17% | 12% | 4% | 11% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 279 | 0.04 | 0 | 279 | 2025-04-22 17:25:20 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 |
| Diluted EPS (Rs.) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 |
| Cash EPS (Rs.) | 11.48 | 9.54 | 4.25 | 11.82 | 9.83 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 72.15 | 63.36 | 54.40 | 55.56 | 48.50 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 72.15 | 63.36 | 54.40 | 55.56 | 48.50 |
| Revenue From Operations / Share (Rs.) | 88.29 | 83.79 | 61.67 | 61.41 | 66.53 |
| PBDIT / Share (Rs.) | 16.38 | 14.30 | 7.02 | 14.12 | 14.71 |
| PBIT / Share (Rs.) | 12.51 | 10.58 | 3.22 | 10.32 | 12.08 |
| PBT / Share (Rs.) | 10.42 | 7.81 | 0.63 | 8.09 | 10.76 |
| Net Profit / Share (Rs.) | 7.60 | 5.81 | 0.45 | 8.02 | 7.20 |
| NP After MI And SOA / Share (Rs.) | 7.80 | 5.89 | -0.83 | 7.35 | 7.39 |
| PBDIT Margin (%) | 18.55 | 17.07 | 11.37 | 22.99 | 22.11 |
| PBIT Margin (%) | 14.16 | 12.62 | 5.22 | 16.80 | 18.16 |
| PBT Margin (%) | 11.79 | 9.32 | 1.02 | 13.17 | 16.17 |
| Net Profit Margin (%) | 8.61 | 6.93 | 0.74 | 13.05 | 10.82 |
| NP After MI And SOA Margin (%) | 8.83 | 7.02 | -1.35 | 11.96 | 11.10 |
| Return on Networth / Equity (%) | 10.80 | 9.29 | -1.53 | 13.23 | 15.23 |
| Return on Capital Employeed (%) | 13.38 | 12.75 | 4.36 | 13.17 | 16.54 |
| Return On Assets (%) | 5.99 | 4.81 | -0.80 | 7.23 | 7.69 |
| Long Term Debt / Equity (X) | 0.21 | 0.22 | 0.26 | 0.31 | 0.36 |
| Total Debt / Equity (X) | 0.48 | 0.52 | 0.54 | 0.55 | 0.53 |
| Asset Turnover Ratio (%) | 0.71 | 0.74 | 0.60 | 0.61 | 0.78 |
| Current Ratio (X) | 1.71 | 1.62 | 1.61 | 1.92 | 1.59 |
| Quick Ratio (X) | 0.83 | 0.91 | 0.73 | 0.64 | 0.88 |
| Inventory Turnover Ratio (X) | 1.94 | 1.86 | 1.26 | 1.99 | 2.35 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 5.09 | -35.97 | 4.08 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 3.12 | 10.13 | 2.69 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 94.91 | 135.97 | 95.92 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 96.88 | 89.87 | 97.31 | 0.00 |
| Interest Coverage Ratio (X) | 7.83 | 5.16 | 2.71 | 6.33 | 11.16 |
| Interest Coverage Ratio (Post Tax) (X) | 4.64 | 3.10 | 1.18 | 4.60 | 6.46 |
| Enterprise Value (Cr.) | 2154.80 | 1748.52 | 734.33 | 1007.49 | 1231.25 |
| EV / Net Operating Revenue (X) | 2.75 | 2.47 | 1.41 | 1.94 | 2.19 |
| EV / EBITDA (X) | 14.84 | 14.44 | 12.36 | 8.43 | 9.88 |
| MarketCap / Net Operating Revenue (X) | 2.41 | 2.13 | 0.93 | 1.53 | 1.87 |
| Retention Ratios (%) | 0.00 | 94.90 | 135.97 | 95.91 | 0.00 |
| Price / BV (X) | 2.95 | 2.81 | 1.06 | 1.69 | 2.57 |
| Price / Net Operating Revenue (X) | 2.41 | 2.13 | 0.93 | 1.53 | 1.87 |
| EarningsYield | 0.03 | 0.03 | -0.01 | 0.07 | 0.05 |
After reviewing the key financial ratios for SMS Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.16. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 8.16, marking an increase of 2.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.16. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 8.16, marking an increase of 2.27.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.48. This value is within the healthy range. It has increased from 9.54 (Mar 24) to 11.48, marking an increase of 1.94.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.15. It has increased from 63.36 (Mar 24) to 72.15, marking an increase of 8.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.15. It has increased from 63.36 (Mar 24) to 72.15, marking an increase of 8.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 88.29. It has increased from 83.79 (Mar 24) to 88.29, marking an increase of 4.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 16.38. This value is within the healthy range. It has increased from 14.30 (Mar 24) to 16.38, marking an increase of 2.08.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.51. This value is within the healthy range. It has increased from 10.58 (Mar 24) to 12.51, marking an increase of 1.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.42. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 10.42, marking an increase of 2.61.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 5.81 (Mar 24) to 7.60, marking an increase of 1.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.80. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 7.80, marking an increase of 1.91.
- For PBDIT Margin (%), as of Mar 25, the value is 18.55. This value is within the healthy range. It has increased from 17.07 (Mar 24) to 18.55, marking an increase of 1.48.
- For PBIT Margin (%), as of Mar 25, the value is 14.16. This value is within the healthy range. It has increased from 12.62 (Mar 24) to 14.16, marking an increase of 1.54.
- For PBT Margin (%), as of Mar 25, the value is 11.79. This value is within the healthy range. It has increased from 9.32 (Mar 24) to 11.79, marking an increase of 2.47.
- For Net Profit Margin (%), as of Mar 25, the value is 8.61. This value is within the healthy range. It has increased from 6.93 (Mar 24) to 8.61, marking an increase of 1.68.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 7.02 (Mar 24) to 8.83, marking an increase of 1.81.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.80. This value is below the healthy minimum of 15. It has increased from 9.29 (Mar 24) to 10.80, marking an increase of 1.51.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.38. This value is within the healthy range. It has increased from 12.75 (Mar 24) to 13.38, marking an increase of 0.63.
- For Return On Assets (%), as of Mar 25, the value is 5.99. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 5.99, marking an increase of 1.18.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.22 (Mar 24) to 0.21, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.48. This value is within the healthy range. It has decreased from 0.52 (Mar 24) to 0.48, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has decreased from 0.74 (Mar 24) to 0.71, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has increased from 1.62 (Mar 24) to 1.71, marking an increase of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.91 (Mar 24) to 0.83, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.94. This value is below the healthy minimum of 4. It has increased from 1.86 (Mar 24) to 1.94, marking an increase of 0.08.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 5.09 (Mar 24) to 0.00, marking a decrease of 5.09.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 3.12 (Mar 24) to 0.00, marking a decrease of 3.12.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 94.91 (Mar 24) to 0.00, marking a decrease of 94.91.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 96.88 (Mar 24) to 0.00, marking a decrease of 96.88.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 5.16 (Mar 24) to 7.83, marking an increase of 2.67.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.64. This value is within the healthy range. It has increased from 3.10 (Mar 24) to 4.64, marking an increase of 1.54.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,154.80. It has increased from 1,748.52 (Mar 24) to 2,154.80, marking an increase of 406.28.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.75. This value is within the healthy range. It has increased from 2.47 (Mar 24) to 2.75, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 14.84. This value is within the healthy range. It has increased from 14.44 (Mar 24) to 14.84, marking an increase of 0.40.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.41, marking an increase of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 94.90 (Mar 24) to 0.00, marking a decrease of 94.90.
- For Price / BV (X), as of Mar 25, the value is 2.95. This value is within the healthy range. It has increased from 2.81 (Mar 24) to 2.95, marking an increase of 0.14.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.41, marking an increase of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in SMS Pharmaceuticals Ltd:
- Net Profit Margin: 8.61%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.38% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.8% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.64
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.83
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.6 (Industry average Stock P/E: 55.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.48
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.61%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 72, H.No. 8-2-334 / 3 & 4, Road No. 5, Opp. SBI Executive Enclave, Hyderabad Telangana 500034 | info@smspharma.com http://www.smspharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramesh Babu Potluri | Chairman & Managing Director |
| Mr. Vamsi Krishna Potluri | Executive Director |
| Mr. Sarath Kumar Pakalapati | Independent Director |
| Mr. Sharvan Kudaravalli | Independent Director |
| Mr. Sarvepalli Srinivas | Independent Director |
| Dr.(Mrs.) Neelaveni Thummala | Independent Director |
FAQ
What is the intrinsic value of SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd's intrinsic value (as of 08 November 2025) is 258.18 which is 10.66% lower the current market price of 289.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,709 Cr. market cap, FY2025-2026 high/low of 312/175, reserves of ₹664 Cr, and liabilities of 1,186 Cr.
What is the Market Cap of SMS Pharmaceuticals Ltd?
The Market Cap of SMS Pharmaceuticals Ltd is 2,709 Cr..
What is the current Stock Price of SMS Pharmaceuticals Ltd as on 08 November 2025?
The current stock price of SMS Pharmaceuticals Ltd as on 08 November 2025 is 289.
What is the High / Low of SMS Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of SMS Pharmaceuticals Ltd stocks is 312/175.
What is the Stock P/E of SMS Pharmaceuticals Ltd?
The Stock P/E of SMS Pharmaceuticals Ltd is 38.6.
What is the Book Value of SMS Pharmaceuticals Ltd?
The Book Value of SMS Pharmaceuticals Ltd is 75.9.
What is the Dividend Yield of SMS Pharmaceuticals Ltd?
The Dividend Yield of SMS Pharmaceuticals Ltd is 0.14 %.
What is the ROCE of SMS Pharmaceuticals Ltd?
The ROCE of SMS Pharmaceuticals Ltd is 12.2 %.
What is the ROE of SMS Pharmaceuticals Ltd?
The ROE of SMS Pharmaceuticals Ltd is 11.0 %.
What is the Face Value of SMS Pharmaceuticals Ltd?
The Face Value of SMS Pharmaceuticals Ltd is 1.00.